Menlo Security Joins VMware SD-WAN Security Technology Partner Program to Deliver Secure Cloud Transformation
Menlo Security, a leader in cloud security, today announced a new integration with VMware SD-WAN by VeloCloud, which offers the industry’s most flexible enterprise SD-WAN architecture. The solution delivers Secure Cloud Transformation, which optimizes and secures local Internet breakouts and enables global low latency access to the Internet and business-critical SaaS applications for an enterprise’s entire local and remote workforce. The integration is available immediately to all VMware SD-WAN customers.
“Menlo Security helps some of the largest enterprises and government agencies in the world transform their infrastructure and move security to the cloud, while maintaining global visibility and control of their traffic,” said Poornima DeBolle, chief product officer at Menlo Security. “VMware SD-WAN by VeloCloud combined with the Menlo Security Cloud Platform powered by isolation redefines security and provides the industry’s most secure solution for Internet and SaaS applications.”
"VMware SD-WAN provides the optimal combination of intrinsic security in the multi-service Edge for corporate traffic as well as SD-WAN optimized access via our Network of Clouds Service gateways to the innovative Menlo Security Cloud Platform powered by isolation," said Steve Woo, senior director of product management at VMware. "Access to cloud and SaaS applications is automatically provisioned, optimized for performance and secured with VMware SD-WAN and Menlo Security Cloud Platform."
VMware SD-WAN customers have simplified their branch office networking and optimized application performance over the Internet. Secure Cloud Transformation, powered by isolation, allows companies to improve security control and visibility across their SD-WAN deployment. Moving to SD-WAN requires an enterprise to move their security to the cloud since user traffic is not backhauled to a central security stack. Menlo Security Cloud Platform allows users to go directly to the Internet while ensuring consistent and robust security controls, whether they are connecting from HQ, remote offices, on the road or in a coffee shop.
Menlo Security’s customers include some of the largest enterprises and government agencies. The company’s cloud security platform currently processes more than 500 million web requests per day. Among the company’s customers are seven of the 10 largest banks, four of the five largest credit-card issuers and some of the largest energy and transportation companies in the world.
For more information, please send an email to ask@menlosecurity.com.
Additional Resources
- Secure Cloud Transformation
- Menlo Security Secure Web Gateway
- Definitive Guide to Internet Isolation
VMware and SD-WAN by VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
About Menlo Security
Menlo Security protects organizations from cyber attacks by eliminating the threat of malware from the web, documents and email. Its cloud-based Isolation Secure Web Gateway scales to provide comprehensive protection across enterprises of any size, without requiring endpoint software or impacting the end user-experience. The company was named a Visionary in the Gartner Magic Quadrant for the Secure Web Gateway. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC and JP Morgan Chase. Menlo Security is headquartered in Palo Alto, California. For more information, visit https://www.menlosecurity.com or ask@menlosecurity.com
VMware, and VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005218/en/
Contact information
Lexie Janney
Merritt Group for Menlo Security
703.390.1531
janney@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom